MedPath
Found 1 clinical trials|View Analysis
Sort by:

First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS)

Phase 1
Recruiting
Conditions
Mutation in the Superoxide Dismutase-1 (SOD1) Gene
Amyotrophic Lateral Sclerosis (ALS)
Interventions
Drug: ALN-SOD
Other: Diluent
Drug: Placebo (PB)
First Posted Date
2024-04-08
Last Posted Date
2024-12-24
Lead Sponsor
Regeneron Pharmaceuticals
Target Recruit Count
42
Registration Number
NCT06351592
Locations
🇨🇦

University of Alberta Hospital, Edmonton, Division of Neurology, Edmonton, Alberta, Canada

🇨🇦

University Hospital - London Health Sciences Centre, London, Ontario, Canada

🇨🇦

Sunnybrook Research Institute, Toronto, Ontario, Canada

and more 3 locations
© Copyright 2025. All Rights Reserved by MedPath